The immunophenotype of adult acute myeloid leukemia: high frequency of lymphoid antigen expression and comparison of immunophenotype, French-American-British classification, and karyotypic abnormalities
Hasan S. Khalidi,L. Jeffrey Medeiros,Karen L. Chang,Russell K. Brynes,Marilyn L. Slovak,Daniel A. Arber +5 more
Reads0
Chats0
TLDR
Immunophenotyping studies are helpful in the determination of myeloid lineage, however, they are not sufficiently specific alone to be useful in precisely identifying either FAB or cytogenetically defined disease subtypes.Abstract:
Immunophenotyping has become common in the diagnosis and classification of acute leukemias and is particularly important in the proper identification of cases of minimally differentiated acute myeloid leukemia (AML-M0). To evaluate the immunophenotype of adult AML, 106 cases were studied by cytochemical analysis and by flow cytometry with a panel of 22 antibodies. The results were compared with the French-American-British (FAB) Cooperative Group classification, as well as with available cytogenetic data on each case. CD45, CD33, and CD13 were the most commonly expressed antigens (97.2%, 95.3%, and 94.3%, respectively). Lymphoid-associated antigens were expressed in 48.1% of cases. CD20 was the most commonly expressed lymphoid antigen (17%), although often expressed in only a subpopulation of leukemic cells, followed by CD7 (16%), CD19 (9.8%), CD2 (7.5%), CD3 (6.7%), CD5 (4.8%), and CD10 (2.9%). Some immunophenotypes correlated with FAB type, including increased frequency of CD2 expression in AML-M3; lack of CD4, CD11c, CD36, CD117, and HLA-DR expression in AML-M3; increased frequency of CD20 and CD36 expression and lack of CD34 expression in AML-M5; increased frequency of CD5 expression in AML-M5a; and increased frequency of CD14 expression in AML-M5b, when compared with all other AMLs (P < .05). When compared with AML-M5b, AML-M5a demonstrated a lack of CD4 expression and a high frequency of CD117 expression. Complete morphologic and cytogenetic agreement between AML-M3 and t(15;17) was present, and four of five cases of AML-M4Eo demonstrated inv(16). The remaining case of M4Eo was characterized by a 6;9 translocation, and two other inv(16) cases were not classified as M4Eo. Expression of CD2 was present in two t(15;17) cases and in one inv(16) case, but expression of this antigen was not restricted to AML cases with these karyotypic abnormalities. Similarly, expression of CD19 was not specific for t(8;21) AML. All t(8;21) leukemias demonstrated M2 morphology. With the exception of M3, M4Eo, and a subgroup of M2 leukemias, the FAB classification does not appear to define cytogenetically distinct disease groups in adult AML. Immunophenotypically distinct profiles were identified in the M3 and M5 morphologic groups of the FAB classification. Immunophenotyping studies are helpful in the determination of myeloid lineage. In general, however, they are not sufficiently specific alone to be useful in precisely identifying either FAB or cytogenetically defined disease subtypes.read more
Citations
More filters
Journal ArticleDOI
Flow Cytometry: Principles and Clinical Applications in Hematology
Michael S. Brown,Carl T. Wittwer +1 more
TL;DR: The use of flow cytometry in the clinical laboratory has grown substantially in the past decade due in part to the development of smaller, user-friendly, less-expensive instruments and a continuous increase in the number of clinical applications.
Journal ArticleDOI
Patterns of leukemia incidence in the United States by subtype and demographic characteristics, 1997–2002
TL;DR: Known risk factors are unlikely to explain the observed disparities in leukemia incidence, and further studies of differences in environmental and genetic risk factors in these populations by specific leukemia subtype may provide clues to the etiologies of these malignancies.
Journal ArticleDOI
Distinct gene expression profiles of acute myeloid/T-lymphoid leukemia with silenced CEBPA and mutations in NOTCH1
Bas J. Wouters,Meritxell Alberich Jordà,Karen Keeshan,Irene Louwers,Claudia A.J. Erpelinck-Verschueren,Dennis Tielemans,Anton W. Langerak,Yiping He,Yumi Yashiro-Ohtani,Pu Zhang,Christopher J. Hetherington,Roel G. W. Verhaak,Peter J. M. Valk,Bob Löwenberg,Daniel G. Tenen,Warren S. Pear,Ruud Delwel +16 more
TL;DR: It is found that in these leukemias, the CEBPA gene was silenced, which was associated with frequent promoter hypermethylation, and the enhanced expression of TRIB2, which is identified here as a direct target of the T-cell commitment factor NOTCH1, suggested aberrantly activated Notch signaling.
Journal ArticleDOI
Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes
Arjan A. van de Loosdrecht,Canan Alhan,Marie C. Béné,Matteo G. Della Porta,Angelika M. Dräger,Jean Feuillard,Patricia Font,Ulrich Germing,Detlef Haase,Christa Homburg,Robin M. Ireland,Joop H. Jansen,Wolfgang Kern,Luca Malcovati,Jeroen G. te Marvelde,Ghulam J. Mufti,Kiyoyuki Ogata,Alberto Orfao,Gert J. Ossenkoppele,Anna Porwit,Frank Preijers,Stephen J. Richards,Gerrit Jan Schuurhuis,Dolores Subirá,Peter Valent,Vincent H.J. van der Velden,Paresh Vyas,A.H. Westra,Theo de Witte,Denise A. Wells,Michael R. Loken,Theresia M. Westers +31 more
TL;DR: Despite strong evidence for an impact of FCM in myelodysplastic syndromes, further (prospective) validation of markers and immunophenotypic patterns are required against control patient groups as well as further standardization in multi-center studies.
Journal ArticleDOI
Clinical significance of phenotypic features of blasts in patients with myelodysplastic syndrome.
Kiyoyuki Ogata,Kyoko Nakamura,Norio Yokose,Hideto Tamura,Mikiko Tachibana,Osamu Taniguchi,Rika Iwakiri,Tatsuyuki Hayashi,Hisashi Sakamaki,Yoshiro Murai,Kaoru Tohyama,Shigeru Tomoyasu,Yasunobu Nonaka,Mayumi Mori,Kazuo Dan,Yataro Yoshida +15 more
TL;DR: The EBC phenotype is more immature in myelodysplastic syndrome than in de novo acute myeloid leukemia, and CD7 positivity of EBCs was an independent variable for a poor prognosis in MDS.